BONESUPPORT Signals Strong Growth in Earnings Call

BONESUPPORT HOLDING AB ((SE:BONEX)) has held its Q4 earnings call. Read on for the main highlights of the call.

BONESUPPORT’s latest earnings call struck an upbeat tone, with management emphasizing strong underlying growth, especially in U.S. CERAMENT G, alongside very high gross margins and solid cash generation. While acknowledging FX headwinds, German market weakness, rising commercial costs and regulatory uncertainty, executives projected clear confidence in the company’s long‑term growth trajectory.

Strong Quarterly Revenue Growth

Net sales for Q4 reached about SEK 312–313 million, rising 22% year over year on a reported basis and 36% in constant currencies, highlighting robust underlying demand. Over the last 12 months, revenue grew roughly 31% reported and 40% at constant FX, with antibiotic‑eluting CERAMENT products up about 54% in constant currency.

CERAMENT G U.S. Momentum

CERAMENT G U.S. sales jumped to SEK 207 million in the quarter, up from SEK 154 million a year earlier, underscoring strong traction in the company’s key growth engine. Overall U.S. sales grew roughly 40% at constant exchange rates, supported by new accounts, deeper penetration in existing hospitals and higher sales per working day.

Expanding U.S. Trauma Footprint

Distribution now covers more than 140 Level 1 trauma centers, compared with just 15 at the end of 2024, giving BONESUPPORT a broad platform for future volume gains. Management stressed that while commercial access is in place, clinical adoption within these centers is still early and expected to ramp gradually over time.

Healthy Profitability and Cash Generation

The adjusted operating result reached about SEK 81 million, translating into an adjusted operating margin of roughly 26%, or close to 27% in FX‑adjusted terms versus 22.6% a year earlier. Operating cash flow remained solid at SEK 54 million, and gross margin stayed extremely high at around 95%, despite a slight decline.

Product and Market Expansion

BONESUPPORT launched CERAMENT BVF in spine on an early‑stage basis in the U.S., marking an entry into a new, promising segment. The company also progressed regulatory work by shifting CERAMENT V’s U.S. submission to a De Novo pathway, while Europe and Rest of World sales reached SEK 54 million with 18% constant‑currency growth and strong showings in hybrid markets.

Clinical and Market Access Progress

The clinical footprint is widening from foot and ankle into trauma and revision arthroplasty, supported by encouraging pilot data and collaborations with leading centers. Investments in commercial initiatives such as the EUROW booster and focused training programs are designed to speed up physician adoption and secure more routine use.

Currency Headwinds Mask Underlying Strength

A stronger Swedish krona against the U.S. dollar cut reported top‑line growth to 22%, even though constant‑currency growth stood at 36%. Foreign exchange translation losses of about SEK 2.9 million weighed on the quarter’s reported figures, partially obscuring the true momentum of the U.S. business.

Germany Market Reforms Drag on Europe

Hospital reforms and new surgical protocol programs in Germany continued to depress demand, making the country a notable weak spot within Europe. Management expects the German market to remain sluggish through 2026, meaning other direct and hybrid markets will need to shoulder more of the region’s growth.

Rising Commercial Costs and Distributor Fees

Selling and marketing expenses rose to SEK 128 million from SEK 108.8 million, reflecting heavier investment in the commercial engine and support programs. Distributor commissions and related fees climbed to SEK 85 million from SEK 69.6 million, limiting operating leverage even as margins stayed attractive.

U.S. Tariffs and Margin Pressure

New U.S. tariffs, currently set at 50%, are starting to erode profitability at the margin and contributed to the minor gross margin decline already visible. Management expects the full impact to shave about 0.8 percentage points off U.S. gross margins by late 2026, though the company still anticipates maintaining very high overall margins.

Regulatory Uncertainty for CERAMENT V

The FDA’s decision to move CERAMENT V from a 510(k) process to a De Novo pathway extends the approval timeline and clouds the near‑term sales outlook for that product. Management is proceeding cautiously, effectively assuming minimal CERAMENT V revenue in its 2026 base case despite expecting an approval around mid‑year.

Early Adoption and Evidence Needs in New Segments

Although BONESUPPORT now enjoys strong access to top trauma centers, physicians’ actual usage patterns are still evolving, and many accounts are at an early adoption stage. Spine and revision arthroplasty, in particular, will need additional clinical data and time before they can become meaningful revenue contributors.

Working Capital Timing Effects

Accounts receivable increased at year‑end as some customer payments slipped to just after the holidays, creating short‑term noise in the cash flow profile. Management emphasized that underlying operating cash generation remains healthy, with the timing effects expected to unwind as payments normalize.

Forward-Looking Guidance and Outlook

For 2026, BONESUPPORT is guiding to at least 35% sales growth in constant currencies, underpinned by a strong Q4 exit rate and broadening clinical adoption. The outlook assumes ongoing FX and German headwinds, gradual tariff‑driven margin pressure and little or no CERAMENT V contribution, suggesting potential upside if regulatory and market conditions prove more favorable.

BONESUPPORT’s earnings call painted the picture of a high‑growth, high‑margin medtech company investing aggressively behind its U.S. trauma opportunity while planting seeds in new segments and markets. Despite currency, regulatory and cost headwinds, the business is generating strong cash, and management’s confident growth guidance will likely keep investor attention firmly on the upside potential into 2026.